MBBS · Pharmacology

Unit 9: Anticancer & Targeted Pharmacology MCQs

35 solved multiple choice questions with answers and short explanations.

Q1. Which mechanism best explains the principal pharmacologic action of Cyclophosphamide?

  1. Aalkylates DNA after hepatic activation
  2. Binhibits dihydrofolate reductase at anticancer doses
  3. Cis a pyrimidine analog that inhibits DNA polymerase
  4. Dgenerates free radicals that cause DNA strand breaks
Show answer
Answer: A. alkylates DNA after hepatic activationCyclophosphamide alkylates DNA after hepatic activation. This mechanism accounts for its characteristic pharmacologic effects.
Report a mistake

Q2. Which clinical use is most appropriately associated with Cyclophosphamide?

  1. Acolorectal and several other solid tumors
  2. Blymphomas, leukemias, and selected solid tumors or autoimmune disorders
  3. Cmany hematologic and solid malignancies
  4. Dbreast, ovarian, lung, and other cancers
Show answer
Answer: B. lymphomas, leukemias, and selected solid tumors or autoimmune disordersCyclophosphamide is used for lymphomas, leukemias, and selected solid tumors or autoimmune disorders. Selection still depends on the patient's diagnosis, contraindications, and treatment context.
Report a mistake

Q3. Which adverse effect or toxicity is particularly important to recognize with Cyclophosphamide?

  1. Adose-related cardiomyopathy and myelosuppression
  2. Bmyelosuppression, mucositis, hepatotoxicity, and teratogenicity
  3. Chemorrhagic cystitis and myelosuppression
  4. Dperipheral neuropathy and ileus with relatively little marrow suppression
Show answer
Answer: C. hemorrhagic cystitis and myelosuppressionAn important safety issue with Cyclophosphamide is hemorrhagic cystitis and myelosuppression. Recognizing characteristic toxicity is central to safe pharmacotherapy.
Report a mistake

Q4. A drug alkylates DNA after hepatic activation and is used for lymphomas, leukemias, and selected solid tumors or autoimmune disorders. Which drug best matches this description?

  1. ACisplatin
  2. BMethotrexate
  3. CBleomycin
  4. DCyclophosphamide
Show answer
Answer: D. CyclophosphamideThe description matches Cyclophosphamide: it alkylates DNA after hepatic activation and is used for lymphomas, leukemias, and selected solid tumors or autoimmune disorders.
Report a mistake

Q5. Which mechanism best explains the principal pharmacologic action of Methotrexate?

  1. Ainhibits dihydrofolate reductase at anticancer doses
  2. Binhibits thymidylate synthase after conversion to active metabolites
  3. Cintercalates DNA, inhibits topoisomerase II, and generates free radicals
  4. Dbinds beta-tubulin and prevents microtubule polymerization
Show answer
Answer: A. inhibits dihydrofolate reductase at anticancer dosesMethotrexate inhibits dihydrofolate reductase at anticancer doses. This mechanism accounts for its characteristic pharmacologic effects.
Report a mistake

Q6. Which clinical use is most appropriately associated with Methotrexate?

  1. Aacute myeloid leukemia
  2. Bleukemias, lymphomas, and several solid tumors
  3. Ctesticular cancer and selected lymphomas
  4. Dtesticular, ovarian, bladder, lung, and other cancers
Show answer
Answer: B. leukemias, lymphomas, and several solid tumorsMethotrexate is used for leukemias, lymphomas, and several solid tumors. Selection still depends on the patient's diagnosis, contraindications, and treatment context.
Report a mistake

Q7. Which adverse effect or toxicity is particularly important to recognize with Methotrexate?

  1. Apulmonary fibrosis with relatively limited myelosuppression
  2. Bmyelosuppression, mucositis, and hand-foot syndrome
  3. Cmyelosuppression, mucositis, hepatotoxicity, and teratogenicity
  4. Dperipheral neuropathy and myelosuppression
Show answer
Answer: C. myelosuppression, mucositis, hepatotoxicity, and teratogenicityAn important safety issue with Methotrexate is myelosuppression, mucositis, hepatotoxicity, and teratogenicity. Recognizing characteristic toxicity is central to safe pharmacotherapy.
Report a mistake

Q8. A drug inhibits dihydrofolate reductase at anticancer doses and is used for leukemias, lymphomas, and several solid tumors. Which drug best matches this description?

  1. AImatinib
  2. B5-Fluorouracil
  3. CVincristine
  4. DMethotrexate
Show answer
Answer: D. MethotrexateThe description matches Methotrexate: it inhibits dihydrofolate reductase at anticancer doses and is used for leukemias, lymphomas, and several solid tumors.
Report a mistake

Q9. Which mechanism best explains the principal pharmacologic action of 5-Fluorouracil?

  1. Ainhibits thymidylate synthase after conversion to active metabolites
  2. Bis a pyrimidine analog that inhibits DNA polymerase
  3. Cgenerates free radicals that cause DNA strand breaks
  4. Dstabilizes microtubules and prevents their depolymerization
Show answer
Answer: A. inhibits thymidylate synthase after conversion to active metabolites5-Fluorouracil inhibits thymidylate synthase after conversion to active metabolites. This mechanism accounts for its characteristic pharmacologic effects.
Report a mistake

Q10. Which clinical use is most appropriately associated with 5-Fluorouracil?

  1. Amany hematologic and solid malignancies
  2. Bcolorectal and several other solid tumors
  3. Cleukemias and lymphomas
  4. Dchronic myeloid leukemia with BCR-ABL
Show answer
Answer: B. colorectal and several other solid tumors5-Fluorouracil is used for colorectal and several other solid tumors. Selection still depends on the patient's diagnosis, contraindications, and treatment context.
Report a mistake

Q11. Which adverse effect or toxicity is particularly important to recognize with 5-Fluorouracil?

  1. Aperipheral neuropathy and ileus with relatively little marrow suppression
  2. Bmyelosuppression and cerebellar toxicity at high doses
  3. Cmyelosuppression, mucositis, and hand-foot syndrome
  4. Dnephrotoxicity, ototoxicity, and severe nausea
Show answer
Answer: C. myelosuppression, mucositis, and hand-foot syndromeAn important safety issue with 5-Fluorouracil is myelosuppression, mucositis, and hand-foot syndrome. Recognizing characteristic toxicity is central to safe pharmacotherapy.
Report a mistake

Q12. A drug inhibits thymidylate synthase after conversion to active metabolites and is used for colorectal and several other solid tumors. Which drug best matches this description?

  1. ATrastuzumab
  2. BCytarabine
  3. CPaclitaxel
  4. D5-Fluorouracil
Show answer
Answer: D. 5-FluorouracilThe description matches 5-Fluorouracil: it inhibits thymidylate synthase after conversion to active metabolites and is used for colorectal and several other solid tumors.
Report a mistake

Q13. Which mechanism best explains the principal pharmacologic action of Cytarabine?

  1. Ais a pyrimidine analog that inhibits DNA polymerase
  2. Bintercalates DNA, inhibits topoisomerase II, and generates free radicals
  3. Cbinds beta-tubulin and prevents microtubule polymerization
  4. Dforms DNA cross-links
Show answer
Answer: A. is a pyrimidine analog that inhibits DNA polymeraseCytarabine is a pyrimidine analog that inhibits DNA polymerase. This mechanism accounts for its characteristic pharmacologic effects.
Report a mistake

Q14. Which clinical use is most appropriately associated with Cytarabine?

  1. Atesticular cancer and selected lymphomas
  2. Bacute myeloid leukemia
  3. Cbreast, ovarian, lung, and other cancers
  4. DHER2-positive breast and gastric cancers
Show answer
Answer: B. acute myeloid leukemiaCytarabine is used for acute myeloid leukemia. Selection still depends on the patient's diagnosis, contraindications, and treatment context.
Report a mistake

Q15. Which adverse effect or toxicity is particularly important to recognize with Cytarabine?

  1. Aperipheral neuropathy and myelosuppression
  2. Bdose-related cardiomyopathy and myelosuppression
  3. Cmyelosuppression and cerebellar toxicity at high doses
  4. Dedema, cytopenias, and hepatotoxicity
Show answer
Answer: C. myelosuppression and cerebellar toxicity at high dosesAn important safety issue with Cytarabine is myelosuppression and cerebellar toxicity at high doses. Recognizing characteristic toxicity is central to safe pharmacotherapy.
Report a mistake

Q16. A drug is a pyrimidine analog that inhibits DNA polymerase and is used for acute myeloid leukemia. Which drug best matches this description?

  1. ARituximab
  2. BDoxorubicin
  3. CCisplatin
  4. DCytarabine
Show answer
Answer: D. CytarabineThe description matches Cytarabine: it is a pyrimidine analog that inhibits DNA polymerase and is used for acute myeloid leukemia.
Report a mistake

Q17. Which mechanism best explains the principal pharmacologic action of Doxorubicin?

  1. Aintercalates DNA, inhibits topoisomerase II, and generates free radicals
  2. Bgenerates free radicals that cause DNA strand breaks
  3. Cstabilizes microtubules and prevents their depolymerization
  4. Dinhibits BCR-ABL and several related tyrosine kinases
Show answer
Answer: A. intercalates DNA, inhibits topoisomerase II, and generates free radicalsDoxorubicin intercalates DNA, inhibits topoisomerase II, and generates free radicals. This mechanism accounts for its characteristic pharmacologic effects.
Report a mistake

Q18. Which clinical use is most appropriately associated with Doxorubicin?

  1. Aleukemias and lymphomas
  2. Bmany hematologic and solid malignancies
  3. Ctesticular, ovarian, bladder, lung, and other cancers
  4. DB-cell lymphomas and selected autoimmune disorders
Show answer
Answer: B. many hematologic and solid malignanciesDoxorubicin is used for many hematologic and solid malignancies. Selection still depends on the patient's diagnosis, contraindications, and treatment context.
Report a mistake

Q19. Which adverse effect or toxicity is particularly important to recognize with Doxorubicin?

  1. Anephrotoxicity, ototoxicity, and severe nausea
  2. Bpulmonary fibrosis with relatively limited myelosuppression
  3. Cdose-related cardiomyopathy and myelosuppression
  4. Dcardiac dysfunction and infusion reactions
Show answer
Answer: C. dose-related cardiomyopathy and myelosuppressionAn important safety issue with Doxorubicin is dose-related cardiomyopathy and myelosuppression. Recognizing characteristic toxicity is central to safe pharmacotherapy.
Report a mistake

Q20. A drug intercalates DNA, inhibits topoisomerase II, and generates free radicals and is used for many hematologic and solid malignancies. Which drug best matches this description?

  1. ACyclophosphamide
  2. BBleomycin
  3. CImatinib
  4. DDoxorubicin
Show answer
Answer: D. DoxorubicinThe description matches Doxorubicin: it intercalates DNA, inhibits topoisomerase II, and generates free radicals and is used for many hematologic and solid malignancies.
Report a mistake

Q21. Which mechanism best explains the principal pharmacologic action of Bleomycin?

  1. Agenerates free radicals that cause DNA strand breaks
  2. Bbinds beta-tubulin and prevents microtubule polymerization
  3. Cforms DNA cross-links
  4. Dtargets the HER2 receptor
Show answer
Answer: A. generates free radicals that cause DNA strand breaksBleomycin generates free radicals that cause DNA strand breaks. This mechanism accounts for its characteristic pharmacologic effects.
Report a mistake

Q22. Which clinical use is most appropriately associated with Bleomycin?

  1. Abreast, ovarian, lung, and other cancers
  2. Btesticular cancer and selected lymphomas
  3. Cchronic myeloid leukemia with BCR-ABL
  4. Dlymphomas, leukemias, and selected solid tumors or autoimmune disorders
Show answer
Answer: B. testicular cancer and selected lymphomasBleomycin is used for testicular cancer and selected lymphomas. Selection still depends on the patient's diagnosis, contraindications, and treatment context.
Report a mistake

Q23. Which adverse effect or toxicity is particularly important to recognize with Bleomycin?

  1. Aedema, cytopenias, and hepatotoxicity
  2. Bperipheral neuropathy and ileus with relatively little marrow suppression
  3. Cpulmonary fibrosis with relatively limited myelosuppression
  4. Dinfusion reactions, infections, and hepatitis B reactivation
Show answer
Answer: C. pulmonary fibrosis with relatively limited myelosuppressionAn important safety issue with Bleomycin is pulmonary fibrosis with relatively limited myelosuppression. Recognizing characteristic toxicity is central to safe pharmacotherapy.
Report a mistake

Q24. A drug generates free radicals that cause DNA strand breaks and is used for testicular cancer and selected lymphomas. Which drug best matches this description?

  1. AMethotrexate
  2. BVincristine
  3. CTrastuzumab
  4. DBleomycin
Show answer
Answer: D. BleomycinThe description matches Bleomycin: it generates free radicals that cause DNA strand breaks and is used for testicular cancer and selected lymphomas.
Report a mistake

Q25. Which mechanism best explains the principal pharmacologic action of Vincristine?

  1. Abinds beta-tubulin and prevents microtubule polymerization
  2. Bstabilizes microtubules and prevents their depolymerization
  3. Cinhibits BCR-ABL and several related tyrosine kinases
  4. Dtargets CD20 on B lymphocytes
Show answer
Answer: A. binds beta-tubulin and prevents microtubule polymerizationVincristine binds beta-tubulin and prevents microtubule polymerization. This mechanism accounts for its characteristic pharmacologic effects.
Report a mistake

Q26. Which clinical use is most appropriately associated with Vincristine?

  1. Atesticular, ovarian, bladder, lung, and other cancers
  2. Bleukemias and lymphomas
  3. CHER2-positive breast and gastric cancers
  4. Dleukemias, lymphomas, and several solid tumors
Show answer
Answer: B. leukemias and lymphomasVincristine is used for leukemias and lymphomas. Selection still depends on the patient's diagnosis, contraindications, and treatment context.
Report a mistake

Q27. Which adverse effect or toxicity is particularly important to recognize with Vincristine?

  1. Acardiac dysfunction and infusion reactions
  2. Bperipheral neuropathy and myelosuppression
  3. Cperipheral neuropathy and ileus with relatively little marrow suppression
  4. Dhemorrhagic cystitis and myelosuppression
Show answer
Answer: C. peripheral neuropathy and ileus with relatively little marrow suppressionAn important safety issue with Vincristine is peripheral neuropathy and ileus with relatively little marrow suppression. Recognizing characteristic toxicity is central to safe pharmacotherapy.
Report a mistake

Q28. A drug binds beta-tubulin and prevents microtubule polymerization and is used for leukemias and lymphomas. Which drug best matches this description?

  1. A5-Fluorouracil
  2. BPaclitaxel
  3. CRituximab
  4. DVincristine
Show answer
Answer: D. VincristineThe description matches Vincristine: it binds beta-tubulin and prevents microtubule polymerization and is used for leukemias and lymphomas.
Report a mistake

Q29. Which mechanism best explains the principal pharmacologic action of Paclitaxel?

  1. Astabilizes microtubules and prevents their depolymerization
  2. Bforms DNA cross-links
  3. Ctargets the HER2 receptor
  4. Dalkylates DNA after hepatic activation
Show answer
Answer: A. stabilizes microtubules and prevents their depolymerizationPaclitaxel stabilizes microtubules and prevents their depolymerization. This mechanism accounts for its characteristic pharmacologic effects.
Report a mistake

Q30. Which clinical use is most appropriately associated with Paclitaxel?

  1. Achronic myeloid leukemia with BCR-ABL
  2. Bbreast, ovarian, lung, and other cancers
  3. CB-cell lymphomas and selected autoimmune disorders
  4. Dcolorectal and several other solid tumors
Show answer
Answer: B. breast, ovarian, lung, and other cancersPaclitaxel is used for breast, ovarian, lung, and other cancers. Selection still depends on the patient's diagnosis, contraindications, and treatment context.
Report a mistake

Q31. Which adverse effect or toxicity is particularly important to recognize with Paclitaxel?

  1. Ainfusion reactions, infections, and hepatitis B reactivation
  2. Bnephrotoxicity, ototoxicity, and severe nausea
  3. Cperipheral neuropathy and myelosuppression
  4. Dmyelosuppression, mucositis, hepatotoxicity, and teratogenicity
Show answer
Answer: C. peripheral neuropathy and myelosuppressionAn important safety issue with Paclitaxel is peripheral neuropathy and myelosuppression. Recognizing characteristic toxicity is central to safe pharmacotherapy.
Report a mistake

Q32. A drug stabilizes microtubules and prevents their depolymerization and is used for breast, ovarian, lung, and other cancers. Which drug best matches this description?

  1. ACytarabine
  2. BCisplatin
  3. CCyclophosphamide
  4. DPaclitaxel
Show answer
Answer: D. PaclitaxelThe description matches Paclitaxel: it stabilizes microtubules and prevents their depolymerization and is used for breast, ovarian, lung, and other cancers.
Report a mistake

Q33. Which mechanism best explains the principal pharmacologic action of Cisplatin?

  1. Aforms DNA cross-links
  2. Binhibits BCR-ABL and several related tyrosine kinases
  3. Ctargets CD20 on B lymphocytes
  4. Dinhibits dihydrofolate reductase at anticancer doses
Show answer
Answer: A. forms DNA cross-linksCisplatin forms DNA cross-links. This mechanism accounts for its characteristic pharmacologic effects.
Report a mistake

Q34. Which clinical use is most appropriately associated with Cisplatin?

  1. AHER2-positive breast and gastric cancers
  2. Btesticular, ovarian, bladder, lung, and other cancers
  3. Clymphomas, leukemias, and selected solid tumors or autoimmune disorders
  4. Dacute myeloid leukemia
Show answer
Answer: B. testicular, ovarian, bladder, lung, and other cancersCisplatin is used for testicular, ovarian, bladder, lung, and other cancers. Selection still depends on the patient's diagnosis, contraindications, and treatment context.
Report a mistake

Q35. Which adverse effect or toxicity is particularly important to recognize with Cisplatin?

  1. Ahemorrhagic cystitis and myelosuppression
  2. Bedema, cytopenias, and hepatotoxicity
  3. Cnephrotoxicity, ototoxicity, and severe nausea
  4. Dmyelosuppression, mucositis, and hand-foot syndrome
Show answer
Answer: C. nephrotoxicity, ototoxicity, and severe nauseaAn important safety issue with Cisplatin is nephrotoxicity, ototoxicity, and severe nausea. Recognizing characteristic toxicity is central to safe pharmacotherapy.
Report a mistake